Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO NOVUM 10 11 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO NOVUM 10 11 28.
ORTHO TRI-CYCLEN 21 vs ORTHO-NOVUM 10/11-28
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback inhibition of hypothalamic-pituitary axis, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Prevention of pregnancy
Prevention of pregnancyTreatment of moderate acne vulgaris (in females ≥15 years who have menarche and desire contraception)Off-label: menstrual cycle regulation, dysmenorrhea, endometriosis-associated pain
One tablet daily for 21 days, followed by 7 days of placebo, then repeat. Each tablet contains 0.180 mg norgestimate and 0.035 mg ethinyl estradiol (days 1–7), 0.215 mg/0.035 mg (days 8–14), and 0.250 mg/0.035 mg (days 15–21). Oral route.
One tablet daily for 28 days, starting on day 1 of menstrual cycle. Each tablet contains 1 mg norethindrone and 10 mcg ethinyl estradiol for first 10 tablets, then 1 mg norethindrone and 35 mcg ethinyl estradiol for next 11 tablets, followed by 7 placebo tablets.
None Documented
None Documented
Norgestimate: ~24 hours (terminal); ethinyl estradiol: ~17 hours (terminal). Steady-state achieved within 5-7 days; clinical significance: missed doses may increase contraceptive failure risk.
Norethindrone: 5-14 hours; Ethinyl estradiol: 8-20 hours. Steady state reached within 5 days. Clinical significance: missed doses may increase pregnancy risk due to rapid decline.
Norgestimate: hydrolyzed to norelgestromin and norgestrel; metabolized by CYP3A4, CYP2C9, and CYP2C19. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes first-pass metabolism with extensive conjugation (glucuronidation and sulfation). Norethindrone: metabolized via reduction, conjugation (glucuronidation), and hydroxylation; also involves CYP3A4 to a lesser extent.
Renal: ~70% (metabolites, primarily glucuronide and sulfate conjugates of norgestimate and ethinyl estradiol); Fecal: ~30% (biliary elimination of unchanged drug and metabolites).
Renal (50-60% as metabolites, <10% unchanged); fecal (30-40%) with biliary elimination of conjugates.
Norgestimate: ~99% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin; norethindrone (active metabolite) binds with similar high affinity.
Norethindrone: 61% bound to albumin and 36% to SHBG; Ethinyl estradiol: 98% bound to albumin.
Norgestimate: Vd ~6-8 L/kg; ethinyl estradiol: Vd ~3-5 L/kg. Large Vd indicates extensive tissue distribution including breast, uterine, and hepatic tissues; clinical relevance: potential for drug interactions (e.g., enzyme inducers).
Norethindrone: 4 L/kg; Ethinyl estradiol: 4-5 L/kg. Indicates extensive tissue distribution.
Oral: Norgestimate ~75% (first-pass metabolism limits bioavailability); ethinyl estradiol ~40-60% (substantial first-pass effect).
Oral: Norethindrone ~64%; Ethinyl estradiol ~45% (due to first-pass metabolism).
No specific dose adjustment is provided in manufacturer labeling; use with caution in patients with renal impairment. GFR-based adjustments are not established.
No specific dose adjustment guidelines for renal impairment. Use with caution in patients with renal impairment, as ethinyl estradiol and norethindrone may accumulate. Monitor for fluid retention and hypertension.
Contraindicated in patients with hepatic disease or hepatocellular carcinoma. Child-Pugh class B or C: contraindicated. Child-Pugh class A: use with caution, no specific dose adjustment defined.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) due to potential accumulation and hepatotoxicity. For mild to moderate impairment (Child-Pugh A or B), use with caution; no specific dose adjustment, but monitor liver function tests.
Safety and efficacy established in postmenarchal females; dosing is same as adult: one tablet daily for 21 days. Weight-based dosing not applicable.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily for 28 days). Safety and efficacy in adolescents have not been specifically established; however, use is common off-label.
Not indicated for use in postmenopausal women. No specific considerations available.
Not indicated for use after menopause. No specific geriatric dosing; however, elderly women should not use combination hormonal contraceptives due to increased risk of thromboembolic events and cardiovascular disease. Use alternative contraception if needed.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events (myocardial infarction, thromboembolism, stroke) from combination hormonal contraceptive use. Risk increases with age and with smoking intensity (especially >15 cigarettes/day). Women >35 years who smoke should not use this medication.
["Thrombotic disorders (e.g., thrombophlebitis, pulmonary embolism, stroke, myocardial infarction)","Hepatic disease (including hepatic adenoma or carcinoma)","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism disturbances","Headache (including migraine with focal symptoms)","Uterine bleeding irregularities"]
["Thromboembolic disorders (DVT, PE, arterial thrombosis, stroke, MI) – increased risk especially in smokers >35 years, obese, or with hypertension","Cerebrovascular disease","Hepatic disease (including hepatic adenoma or impaired liver function)","Gallbladder disease","Hypertension","Glucose intolerance/diabetes mellitus","Headache (including migraine with or without aura)","Uterine bleeding irregularities","Depression","Possible increased risk of cervical cancer with long-term use"]
["Known or suspected pregnancy","Current or history of thromboembolic disorders (e.g., DVT, PE)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal genital bleeding","Hepatic adenoma or carcinoma, or active liver disease","Hypersensitivity to any component","Smoking in women over 35 years","Uncontrolled hypertension","Diabetes with vascular involvement","Migraine with aura if >35 years","Major surgery with prolonged immobilization"]
["Known or suspected pregnancy","Current or past thromboembolic disorders (DVT, PE, stroke, MI)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Estrogen-dependent neoplasia","Hepatic adenomas or carcinomas, or active liver disease (e.g., acute hepatitis)","Undiagnosed abnormal uterine bleeding","Heavy smoking (>15 cigarettes/day) in women ≥35 years"]
Data Pending Review
Data Pending Review
No specific food restrictions; however, grapefruit juice may increase estrogen levels (minor interaction). Avoid St. John's wort, which can reduce contraceptive efficacy.
No specific food interactions. Grapefruit juice may increase ethinyl estradiol levels, but clinical significance is minimal. Maintain consistent diet. Antacids containing magnesium may reduce absorption if taken within 2 hours. Caution with St. John's Wort, as it may reduce contraceptive efficacy.
First trimester: Risk of congenital anomalies (limb defects, neural tube defects) based on case reports; overall risk low. Second/third trimester: Possible increased risk of intrauterine growth restriction and preterm birth. Postnatal: Potential for jaundice and transient hormonal effects in neonates.
First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction, preterm birth, and transient metabolic disturbances. Contraindicated during pregnancy (FDA Category X).
Contraindicated in breastfeeding due to estrogens reducing milk production and quality. Limited data; M/P ratio not established. Alternative methods preferred.
Excreted in breast milk in small amounts; M/P ratio approximately 0.4. May reduce milk production and quality. Use alternative contraception during breastfeeding.
No dose adjustments needed as drug is contraindicated during pregnancy. Discontinue immediately upon confirmed pregnancy; pharmacokinetic changes not applicable.
Contraindicated in pregnancy; no dose adjustment applicable. Discontinue if pregnancy occurs.
Category C
Category C
ORTHO TRI-CYCLEN 21 contains norgestimate and ethinyl estradiol; it is a triphasic oral contraceptive with varying hormone doses across 21 active pills. Its progestin component has low androgenicity, making it suitable for patients with acne or hirsutism. Monitor for thromboembolic risk, especially in smokers over 35. Missed pill management: if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception and consider emergency contraception.
ORTHO-NOVUM 10/11-28 is a biphasic oral contraceptive containing ethinyl estradiol (35 mcg) and norethindrone (0.5 mg/1 mg). The biphasic dosing mimics natural hormonal fluctuations. It is indicated for contraception. Monitor for breakthrough bleeding, especially during the first few cycles. Counsel patients to take at the same time daily and use backup contraception if a dose is missed. Contraindicated in smokers over 35, history of thromboembolism, or migraine with aura.
Take one pill daily at the same time for 21 days, then 7 placebo pills.Use backup contraception (e.g., condoms) for the first 7 days of initial use.Common side effects: nausea, breast tenderness, breakthrough bleeding; these often improve after 2-3 cycles.Report signs of blood clots: leg pain/swelling, chest pain, sudden shortness of breath, severe headache.Smoking increases blood clot risk; do not smoke while using this medication.If severe vomiting or diarrhea occurs within 4 hours after taking a pill, consider it missed and follow missed pill instructions.
Take one tablet daily at the same time, following the scheduled order in the pack.Missing pills increases risk of pregnancy; refer to package insert for missed dose instructions.Use backup non-hormonal contraception for 7 days if you miss a dose or start late.Common side effects: nausea, breast tenderness, breakthrough bleeding, and mood changes.Report severe headache, chest pain, leg swelling/pain, or visual disturbances immediately.Smoking while on this pill increases risk of serious cardiovascular events; avoid smoking.Do not take during pregnancy; stop if pregnancy is suspected.